66680-03-3
66680-03-3
Chemical Structure
SKLB325
- CAS No.: 66680-03-3
- Formula:C12H12N4O2
- Molecular Weight:244.25
IUPAC Name: (E)-2-(2-(2-hydroxybenzylidene)hydrazinyl)-6-methylpyrimidin-4-ol
InChIKey: XVDNTAIBZHGIAL-NTUHNPAUSA-N
SMILES: OC1=NC(N/N=C/C2=CC=CC=C2O)=NC(C)=C1
Biological Activity: SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM, and the IC50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis[1]. SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) [2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SKLB325 | 99.21% | SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM, and the IC50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis. SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.67
HY-164055HL1 -
Similarity Score 0.64
HY-135474KM91104 -
Similarity Score 0.64
HY-W009730R2,2'-((1E,1'E)-Hydrazine-1,2-diylidenebis(methanylylidene))diphenol (Standard) -
Similarity Score 0.63
HY-103528RSCS (Standard) -
Similarity Score 0.63
HY-W324882Salinazid -
Similarity Score 0.63
HY-115847(E)-MS0017509 -
Similarity Score 0.62
HY-161071Antioxidant/anticancer agent 1 -
Similarity Score 0.62
HY-123579Androgen receptor ligand 4 -
Similarity Score 0.60
HY-178482HDZI 2,4OH -
Explore the MedChemAI to find more analogs
References
- [1]. Heng Zheng, et al. Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer. Signal Transduct Target Ther.2019 Jul 26;4:24. [Content Brief]
- [2]. Chuanjie Zhang, et al. Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma. Clin Transl Med. 2021 Feb;11(2):e328. [Content Brief]
